Do analysts recommend ATHX or SXTP?

60 Degrees Pharmaceuticals has a consensus target price of $13.85, suggesting a potential upside of 1,093.97%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Athersys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 60 Degrees Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ATHX or SXTP more profitable?

Athersys has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%. Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% 60 Degrees Pharmaceuticals -650.21% N/A -136.81%

Do analysts recommend ATHX or XRTX?

Given Athersys' higher probable upside, research analysts clearly believe Athersys is more favorable than XORTX Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ATHX or XRTX more profitable?

Athersys' return on equity of 0.00% beat XORTX Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% XORTX Therapeutics N/A -137.85% -108.16%

Do analysts rate ATHX or SILO?

Given Athersys' higher probable upside, equities analysts plainly believe Athersys is more favorable than Silo Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ATHX or SILO more profitable?

Athersys has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Athersys' return on equity of 0.00% beat Silo Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% Silo Pharma -6,726.39% -81.75% -66.35%

Do analysts rate JUNS or ATHX?

Given Athersys' higher probable upside, analysts clearly believe Athersys is more favorable than Jupiter Neurosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is JUNS or ATHX more profitable?

Athersys' return on equity of 0.00% beat Jupiter Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Jupiter Neurosciences N/A -1,314.62% -246.66% Athersys N/A N/A -223.03%

Which has stronger earnings and valuation, VCNX or ATHX?

Vaccinex has higher revenue and earnings than Athersys. Vaccinex is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaccinex $388K 6.70 -$20.25M -$48.27 N/A Athersys $146K 0.00 -$72.53M -$2.03 N/A

Is VCNX or ATHX more profitable?

Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% Athersys N/A N/A -223.03%

Athersys (ATHX) Competitors

Compare

ATHX vs. SXTP, XRTX, SILO, JUNS, and VCNX

Should you buy Athersys stock or one of its competitors? Athersys's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTP), XORTX Therapeutics (XRTX), Silo Pharma (SILO), Jupiter Neurosciences (JUNS), and Vaccinex (VCNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Athersys compare to 60 Degrees Pharmaceuticals?

Athersys (NASDAQ:ATHX) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Athersys has a beta of -0.9, suggesting that its stock price is 190% less volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.54, suggesting that its stock price is 154% more volatile than the broader market.

60 Degrees Pharmaceuticals has a consensus target price of $13.85, suggesting a potential upside of 1,093.97%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Athersys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

60 Degrees Pharmaceuticals has higher revenue and earnings than Athersys. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
60 Degrees Pharmaceuticals	$1.41M	2.90	-$7.36M	-$4.82	N/A

19.4% of Athersys shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 0.0% of Athersys shares are owned by company insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Athersys has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%.

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
60 Degrees Pharmaceuticals	-650.21%	N/A	-136.81%

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Athersys. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Athersys. 60 Degrees Pharmaceuticals' average media sentiment score of 0.42 beat Athersys' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Athersys	Neutral
60 Degrees Pharmaceuticals	Neutral

Summary

60 Degrees Pharmaceuticals beats Athersys on 10 of the 14 factors compared between the two stocks.

How does Athersys compare to XORTX Therapeutics?

Athersys (NASDAQ:ATHX) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

Given Athersys' higher probable upside, research analysts clearly believe Athersys is more favorable than XORTX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

XORTX Therapeutics has lower revenue, but higher earnings than Athersys. XORTX Therapeutics is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.73	N/A

In the previous week, XORTX Therapeutics had 4 more articles in the media than Athersys. MarketBeat recorded 4 mentions for XORTX Therapeutics and 0 mentions for Athersys. XORTX Therapeutics' average media sentiment score of 0.15 beat Athersys' score of 0.00 indicating that XORTX Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Athersys	Neutral
XORTX Therapeutics	Neutral

19.4% of Athersys shares are owned by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are owned by institutional investors. 0.0% of Athersys shares are owned by insiders. Comparatively, 6.9% of XORTX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Athersys' return on equity of 0.00% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
XORTX Therapeutics	N/A	-137.85%	-108.16%

Athersys has a beta of -0.9, meaning that its stock price is 190% less volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

Summary

XORTX Therapeutics beats Athersys on 7 of the 13 factors compared between the two stocks.

How does Athersys compare to Silo Pharma?

Athersys (NASDAQ:ATHX) and Silo Pharma (NASDAQ:SILO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Given Athersys' higher probable upside, equities analysts plainly believe Athersys is more favorable than Silo Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Silo Pharma had 4 more articles in the media than Athersys. MarketBeat recorded 4 mentions for Silo Pharma and 0 mentions for Athersys. Silo Pharma's average media sentiment score of 0.50 beat Athersys' score of 0.00 indicating that Silo Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Athersys	Neutral
Silo Pharma	Neutral

19.4% of Athersys shares are owned by institutional investors. Comparatively, 5.6% of Silo Pharma shares are owned by institutional investors. 0.0% of Athersys shares are owned by company insiders. Comparatively, 3.6% of Silo Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Silo Pharma has lower revenue, but higher earnings than Athersys. Silo Pharma is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
Silo Pharma	$70K	40.20	-$4.23M	-$4.36	N/A

Athersys has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Athersys' return on equity of 0.00% beat Silo Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Silo Pharma	-6,726.39%	-81.75%	-66.35%

Athersys has a beta of -0.9, indicating that its stock price is 190% less volatile than the broader market. Comparatively, Silo Pharma has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

Summary

Athersys and Silo Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Athersys compare to Jupiter Neurosciences?

Jupiter Neurosciences (NASDAQ:JUNS) and Athersys (NASDAQ:ATHX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

19.4% of Athersys shares are held by institutional investors. 38.6% of Jupiter Neurosciences shares are held by insiders. Comparatively, 0.0% of Athersys shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Jupiter Neurosciences had 1 more articles in the media than Athersys. MarketBeat recorded 1 mentions for Jupiter Neurosciences and 0 mentions for Athersys. Jupiter Neurosciences' average media sentiment score of 0.00 equaled Athersys'average media sentiment score.

Company	Overall Sentiment
Jupiter Neurosciences	Neutral
Athersys	Neutral

Jupiter Neurosciences has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market. Comparatively, Athersys has a beta of -0.9, meaning that its stock price is 190% less volatile than the broader market.

Given Athersys' higher probable upside, analysts clearly believe Athersys is more favorable than Jupiter Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Athersys' return on equity of 0.00% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-246.66%
Athersys	N/A	N/A	-223.03%

Jupiter Neurosciences has higher earnings, but lower revenue than Athersys. Jupiter Neurosciences is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$64.69K	41.92	-$8.65M	-$19.12	N/A
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A

Summary

Athersys beats Jupiter Neurosciences on 7 of the 12 factors compared between the two stocks.

How does Athersys compare to Vaccinex?

Vaccinex (NASDAQ:VCNX) and Athersys (NASDAQ:ATHX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Athersys	N/A	N/A	-223.03%

Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Athersys has a beta of -0.9, suggesting that its stock price is 190% less volatile than the broader market.

50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 19.4% of Athersys shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by insiders. Comparatively, 0.0% of Athersys shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Vaccinex has higher revenue and earnings than Athersys. Vaccinex is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	6.70	-$20.25M	-$48.27	N/A
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A

In the previous week, Vaccinex's average media sentiment score of 0.00 equaled Athersys'average media sentiment score.

Company	Overall Sentiment
Vaccinex	Neutral
Athersys	Neutral

Summary

Vaccinex beats Athersys on 5 of the 8 factors compared between the two stocks.

Get Athersys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATHX vs. The Competition

Export

Metric	Athersys	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$833K	$12.61B	$7.31B	$13.28B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	0.00	792.28	274.10	25.70
Price / Sales	N/A	857.09	672.61	90.85
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	N/A	10.57	10.48	6.32
Net Income	-$72.53M	$2.81B	$3.49B	$359.73M

Athersys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATHX Athersys	N/A	N/A	N/A	N/A	$833K	$146K	N/A	24
SXTP 60 Degrees Pharmaceuticals	1.8902 of 5 stars	$0.94 +1.9%	$13.85 +1,370.3%	-79.1%	$3.32M	$1.41M	N/A	3	Analyst Forecast
XRTX XORTX Therapeutics	0.8125 of 5 stars	$1.68 -5.8%	N/A	-60.9%	$3.05M	N/A	N/A	N/A	Analyst Forecast Gap Down
SILO Silo Pharma	1.0752 of 5 stars	$1.77 +0.3%	N/A	-85.5%	$2.81M	$70K	N/A	2	Positive News
JUNS Jupiter Neurosciences	0.0919 of 5 stars	$3.00 +2.4%	N/A	-97.0%	$2.73M	$20K	N/A	5	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATHX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Athersys (ATHX) Competitors

ATHX vs. SXTP, XRTX, SILO, JUNS, and VCNX

How does Athersys compare to 60 Degrees Pharmaceuticals?

Summary

How does Athersys compare to XORTX Therapeutics?

Summary

How does Athersys compare to Silo Pharma?

Summary

How does Athersys compare to Jupiter Neurosciences?

Summary

How does Athersys compare to Vaccinex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHX vs. The Competition

Athersys Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Athersys (ATHX) Competitors

ATHX vs. SXTP, XRTX, SILO, JUNS, and VCNX

How does Athersys compare to 60 Degrees Pharmaceuticals?

Which has more volatility & risk, ATHX or SXTP?

Do analysts recommend ATHX or SXTP?

Which has better valuation & earnings, ATHX or SXTP?

Do insiders & institutionals hold more shares of ATHX or SXTP?

Is ATHX or SXTP more profitable?

Does the media prefer ATHX or SXTP?

Summary

How does Athersys compare to XORTX Therapeutics?

Do analysts recommend ATHX or XRTX?

Which has stronger earnings and valuation, ATHX or XRTX?

Does the media refer more to ATHX or XRTX?

Do insiders and institutionals believe in ATHX or XRTX?

Is ATHX or XRTX more profitable?

Which has more risk & volatility, ATHX or XRTX?

Summary

How does Athersys compare to Silo Pharma?

Do analysts rate ATHX or SILO?

Does the media favor ATHX or SILO?

Do insiders and institutionals hold more shares of ATHX or SILO?

Which has better earnings & valuation, ATHX or SILO?

Is ATHX or SILO more profitable?

Which has more risk and volatility, ATHX or SILO?

Summary

How does Athersys compare to Jupiter Neurosciences?

Do institutionals and insiders believe in JUNS or ATHX?

Does the media prefer JUNS or ATHX?

Which has more risk & volatility, JUNS or ATHX?

Do analysts rate JUNS or ATHX?

Is JUNS or ATHX more profitable?

Which has better valuation and earnings, JUNS or ATHX?

Summary

How does Athersys compare to Vaccinex?

Is VCNX or ATHX more profitable?

Which has more volatility & risk, VCNX or ATHX?

Do institutionals and insiders hold more shares of VCNX or ATHX?

Which has stronger earnings and valuation, VCNX or ATHX?

Does the media prefer VCNX or ATHX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHX vs. The Competition

Athersys Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools